Cetuximab injection
Products billed under this code include Erbitux.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Erbitux.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Erbitux | Eli Lilly and Company | 66733-0948-23 | 10 | $808.58 |
| Erbitux | Eli Lilly and Company | 66733-0958-23 | 20 | $1,617.16 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $80.858 | −$0.808 | 10 MG | Cetuximab injection | v1, posted September 17, 2026 |
| 3Q26 | $81.666 | +$1.209 | 10 MG | Cetuximab injection | v1, posted September 15, 2026 |
| 2Q26 | $80.457 | −$0.098 | 10 MG | Cetuximab injection | v1, posted September 15, 2026 |
| 1Q26 | $80.555 | +$2.186 | 10 MG | Cetuximab injection | v1, posted September 15, 2026 |
| 4Q25 | $78.369 | −$0.098 | 10 MG | Cetuximab injection | v1, posted September 8, 2026 |
| 3Q25 | $78.467 | +$0.943 | 10 MG | Cetuximab injection | v1, posted March 10, 2026 |
| 2Q25 | $77.524 | +$0.429 | 10 MG | Cetuximab injection | v1, posted March 10, 2026 |
| 1Q25 | $77.095 | +$1.616 | 10 MG | Cetuximab injection | v1, posted December 19, 2025 |
| 4Q24 | $75.479 | −$0.154 | 10 MG | Cetuximab injection | v1, posted June 11, 2025 |
| 3Q24 | $75.633 | +$2.146 | 10 MG | Cetuximab injection | v1, posted June 11, 2025 |
| 2Q24 | $73.487 | −$0.233 | 10 MG | Cetuximab injection | v1, posted March 11, 2025 |
| 1Q24 | $73.72 | +$1.444 | 10 MG | Cetuximab injection | v1, posted December 19, 2024 |
| 4Q23 | $72.276 | +$0.198 | 10 MG | Cetuximab injection | v1, posted October 10, 2024 |
| 3Q23 | $72.078 | +$1.936 | 10 MG | Cetuximab injection | v1, posted June 5, 2024 |
| 2Q23 | $70.142 | −$0.212 | 10 MG | Cetuximab injection | v1, posted February 23, 2024 |
| 1Q23 | $70.354 | +$1.261 | 10 MG | Cetuximab injection | v1, posted December 6, 2023 |
| 4Q22 | $69.093 | −$0.315 | 10 MG | Cetuximab injection | v1, posted June 22, 2023 |
| 3Q22 | $69.408 | +$1.766 | 10 MG | Cetuximab injection | v1, posted June 9, 2023 |
| 2Q22 | $67.642 | +$0.024 | 10 MG | Cetuximab injection | v1, posted December 14, 2022 |
| 1Q22 | $67.618 | +$0.913 | 10 MG | Cetuximab injection | v1, posted June 8, 2022 |
| 4Q21 | $66.705 | +$0.393 | 10 MG | Cetuximab injection | v1, posted June 2, 2022 |
| 3Q21 | $66.312 | +$1.139 | 10 MG | Cetuximab injection | v1, posted June 2, 2022 |
| 2Q21 | $65.173 | −$0.31 | 10 MG | Cetuximab injection | v1, posted March 1, 2022 |
| 1Q21 | $65.483 | – | 10 MG | Cetuximab injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.